[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-341716-105":59,"doc-detail-341716-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","the-parp1-selective-inhibitor-saruparib-azd5305-elicits-potent-and-durable-antitumor-activity-in-patient-derived-brca12-associated-cancer-models","The PARP1 selective inhibitor saruparib (AZD5305) elicits potent and durable antitumor activity in patient-derived BRCA1/2-associated cancer models","","Poly (ADP-ribose) polymerase 1 and 2 (PARP1/2) inhibitors are targeted therapies for homologous recombination repair (HRR)-deficient breast, ovarian, pancreatic, and prostate cancers. Because PARP1 inhibition can trigger synthetic lethality in homologous recombination deficiency (HRD) tumors, the PARP1-selective inhibitor saruparib (AZD5305) is under development. AZD5305 antitumor activity was characterized in patient-derived preclinical models versus olaparib and resistance mechanisms were investigated.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/the-parp1-selective-inhibitor-saruparib-azd5305-elicits-potent-and-durable-antitumor-activity-in-patient-derived-brca12-associated-cancer-models/341716/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/the-parp1-selective-inhibitor-saruparib-azd5305-elicits-potent-and-durable-antitumor-activity-in-patient-derived-brca12-associated-cancer-models/341716.png","ImageObject",300,407,{"name":92,"@type":93},"Theodore","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-29","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":52},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What is the main goal of this study on AZD5305?","Question",{"text":112,"@type":113},"To characterize the antitumor activity of the PARP1 selective inhibitor AZD5305 in patient-derived preclinical models compared with olaparib and to identify mechanisms of resistance.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"Which models and treatments were used to evaluate AZD5305?",{"text":117,"@type":113},"Thirteen BRCA1/BRCA2/PALB2 mutation patient-derived tumor xenograft (PDX) models were tested using AZD5305 alone or combined with carboplatin or the ATR inhibitor ceralasertib, compared with olaparib.",{"name":119,"@type":110,"acceptedAnswer":120},"What were the key efficacy and mechanistic findings?",{"text":121,"@type":113},"AZD5305 produced a higher preclinical complete response rate than olaparib and longer median progression-free survival. Mechanistically, AZD5305 induced more replication stress and genomic instability, and resistance was associated with increased HRR functionality and BRCA1/BRCA2 reversion or hypomorphic changes.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},341716,1790148906,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":52,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},7971461740886,"https://ap-avatar.wpscdn.com/davatar_3d24733baf745e90a7e4bdd5f77d97b2","Herencia‑Ropero etal. Genome Medicine (2024) 16:107  \n[https://doi.org/10.1](https://doi.org/10.1) 186/s13073‑024‑01370‑z  \nGenome Medicine  \n RESEARCH Open Access  \nThe PARP1  \nselective inhibitor saruparib  \n(AZD5305) elicits potent and durable antitumor activity in patient‑derived BRCA1/2‑associated cancer models  \nAndrea Herencia-Ropero1,2, Alba Llop-Guevara1*, Anna D. Staniszewska3, Joanna Domènech-Vivó4,5, Eduardo García-Galea6, Alejandro Moles-Fernández7,8, Flaminia Pedretti 1, Heura Domènech 1, Olga Rodríguez 1, Marta Guzmán1, Enrique J. Arenas9,10,11, Helena Verdaguer12,13, Fernando J. Calero-Nieto3, Sara Talbot3,  \nLuis Tobalina3, Elisabetta Leo3, Alan Lau3, Paolo Nuciforo 14, Rodrigo Dienstmann6, Teresa Macarulla 12,13, Joaquín Arribas9,10,15,16,17, Orland Díez4,8, Sara Gutiérrez-Enríquez4, Josep V. Forment3, Mark J. O’Connor3, Mark Albertella3, Judith Balmaña4,18* and Violeta Serra1*  \nAbstract  \nBackground Poly (ADP-ribose) polymerase 1 and 2 (PARP1/2) inhibitors (PARPi) are targeted therapies approved for homologous recombination repair (HRR)-deficient breast, ovarian, pancreatic, and prostate cancers. Since inhibition of PARP1 is sufficient to cause synthetic lethality in tumors with homologous recombination deficiency (HRD), PARP1 selective inhibitors such as saruparib (AZD5305) are being developed. It is expected that selective PARP1 inhibition leads to a safer profile that facilitates its combination with other DNA damage repair inhibitors. Here, we aimed to characterize the antitumor activity of AZD5305 in patient-derived preclinical models compared to the firstgeneration PARP1/2 inhibitor olaparib and to identify mechanisms of resistance.  \nMethods Thirteen previously characterized patient-derived tumor xenograft (PDX) models from breast, ovarian, and pancreatic cancer patients harboring germline pathogenic alterations in BRCA1, BRCA2, or PALB2 were used to evaluate the efficacy of AZD5305 alone or in combination with carboplatin or an ataxia telangiectasia and Rad3 related (ATR) inhibitor (ceralasertib) and compared it to the first-generation PARPi olaparib. We performed DNA and RNA sequencing as well as protein-based assays to identify mechanisms of acquired resistance to either PARPi. Results AZD5305 showed superior antitumor activity than the first-generation PARPi in terms of preclinical complete response rate (75% vs. 37%) . The median preclinical progression-free survival was significantly longer in the AZD5305-treated group compared to the olaparib-treated group (> 386 days vs. 90 days) . Mechanistically, AZD5305 induced more replication stress and genomic instability than the PARP1/2 inhibitor olaparib in PARPi-sensitive tumors. All  \n*Correspondence: Alba Llop-Guevara [alballop@gmail.com](alballop@gmail.com)[ ](alballop@gmail.com)Judith Balmaña[jbalmana@vhio.net](jbalmana@vhio.net)[ ](jbalmana@vhio.net)Violeta Serra [vserra@vhio.net](vserra@vhio.net)  \nFull list of author information is available at the end of the article  \n© The Author(s) 2024. Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visi","cbCaiiVQc8McYJaO","https://ap.wps.com/l/cbCaiiVQc8McYJaO","pdf",2255090,17,"English","# Abstract\n# Background\n# Methods\n# Results\n# Conclusions\n# Keywords","[{\"question\":\"What is the main goal of this study on AZD5305?\",\"answer\":\"To characterize the antitumor activity of the PARP1 selective inhibitor AZD5305 in patient-derived preclinical models compared with olaparib and to identify mechanisms of resistance.\"},{\"question\":\"Which models and treatments were used to evaluate AZD5305?\",\"answer\":\"Thirteen BRCA1/BRCA2/PALB2 mutation patient-derived tumor xenograft (PDX) models were tested using AZD5305 alone or combined with carboplatin or the ATR inhibitor ceralasertib, compared with olaparib.\"},{\"question\":\"What were the key efficacy and mechanistic findings?\",\"answer\":\"AZD5305 produced a higher preclinical complete response rate than olaparib and longer median progression-free survival. Mechanistically, AZD5305 induced more replication stress and genomic instability, and resistance was associated with increased HRR functionality and BRCA1/BRCA2 reversion or hypomorphic changes.\"}]","The PARP1 selective inhibitor saruparib (AZD5305) elicits potent and durable antitumor activity in patient-derived BRCA1/2-associated cancer models | PDF",1790043348,43,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/0779c9a8b6f10c82b687e8d6b9585d17.webp",983,1305,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/56fac6e235337419ce21b7869e20c97a.webp",982,1304,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/bff2b707c0c6acc6d6ab1f3d0d64feaa.webp",981,1303,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/1d3995f47b82dbe914c044f1d319bb68.webp",980,1301]